Reports and Intelligence: China Monoclonal Antibody (McAB) Industry Market - Size, Share, Global Trends, Demand, Forecast, 2014

1

Research on China Monoclonal Antibody (McAB)
Industry, 2014

Published Huidian Research
No of pages 60
Date July 2014
2
Table Of Content

• Overview of Monoclonal Antibody 
• Operation Environment of China's Monoclonal
  Antibody Industry
• Current Situation and Tendencies of Worldwide
  Monoclonal Antibody Industry
• Operation Situation of China's Monoclonal
  Antibody Industry
• China's Key Monoclonal Antibody Agent Enterprises
• Huge Growth Potential and Development
  Opportunities of China Monoclonal Antibody Market
  in the Future 
• Get full TOC at http//www.reportsandintelligence
  .com/research-on-china-monoclonal-antibody-mcab-in
  dustry-2014-2018-reports-market/table-of-contents

3
Description


Research on China Monoclonal Antibody (McAB)
Industry, 2014 mainly carries on in-depth
analysis on policy environment, global market,
Chinese market, as well as the latest
developments of domestic key enterprises related
to Chinas monoclonal antibody industry.
Several Chinese large-scale pharmaceutical
enterprises devoted themselves to research and
development of monoclonal antibody agents, which
have achieved results in 2013. Hengrui Medicine
Co., Ltd., Shanghai Pharmaceuticals Co., Ltd. and
Qilu Pharm have applied for clinical research of
monoclonal antibody agents. And Walvax
Biotechnology Co., Ltd even made a huge
investment in purchasing Genor Biopharma Co.,
Ltd, attempting to establish a large biological
strategy. Although large-scale pharmaceutical
enterprises entered monoclonal antibody field on
a large scale, the overall innovation is still
insufficient. Detailed Report at
http//www.reportsandintelligence.com/research-on-
china-monoclonal-antibody-mcab-industry-2014-2018-
market
4
Description


The market is represented by monoclonal antibody
agents and biological analogue that have
submitted applications, few imitated drugs, and
innovative medicines are rare and precious
things, mainly on account of high risks and
long-time cycle. Due to late state, Chinas
strength on research and development will be
still vulnerable within future three to five
years, so it has to open the market preliminarily
by depending on generic drugs. In 2013, the
market size was CNY 3.8 billion around, up 30
year-on-year product categories and sales volume
were far less than that of European and American
countries. According to statistical data of
Shanghai Pharmaceutical Profession Association
(SPPA), China will see four to six monoclonal
antibody agents by 2016, such as Trastuzumab and
Rituximab. And it is expected by 2020, six to ten
monoclonal antibody agents will be listed in
market, and some of which are independently
researched drugs. Enquire about Report at
http//www.reportsandintelligence.com/enquire-abou
t-report/114250
5
Similar Reports


Research on Automotive Drive Shaft Market in
China, 2014-2018 http//www.reportsandintelligence
.com/research-on-automotive-drive-shaft-in-china-2
014-2018-reports-market Research and
Development Forecast of Core Drilling Rig Market
in China, 2014 http//www.reportsandintelligence.c
om/research-and-development-forecast-of-core-drill
ing-rig-in-china-2014-reports-market
6

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/research-on-
china-monoclonal-antibody-mcab-industry-2014-2018-
market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com